 | |
| Clinical data | |
|---|---|
| Trade names | Convenia |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy category |
|
| Routes of administration | dorsoscapular subcutaneous injection |
| ATCvet code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | Dogs: 98.5%, Cats: 99.8% |
| Metabolism | none |
| Eliminationhalf-life | Dogs: 133 hours, Cats: 166 hours |
| Excretion | unchanged in urine/bile |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C17H19N5O6S2 |
| Molar mass | 453.49 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Cefovecin (INN) is anantibiotic of thecephalosporin class, licensed for the treatment of skin infections incats anddogs. It is marketed byZoetis under the trade nameConvenia. It is used to treat skin infections caused byPasteurella multocida in cats, andStaphylococcus intermedius andStreptococcus canis in dogs. The advantage of using a long-acting injectable antibiotic is that, unlike in daily administration, doses cannot be missed. Missed doses may allow partially resistant microbes to recover. The disadvantage is the presence of subtherapeutic concentrations in the weeks after the resolution of infections. This is associated with the development of resistance in microbes. It should not be used in pregnant or lactating animals or in animals with a history of allergies topenicillin or cephalosporin drugs.[3]
Cefovecin is a broad-spectrum, third-generationcephalosporinantibiotic administered bysubcutaneous injection.[4] It is used to treat skin and soft tissue infections in dogs and cats.[4] The antimicrobial effects last for 14 days following administration.[5]
In drug studies, cefovecin administered to dogs was 92.4% effective against skin infections (secondary superficialpyoderma,abscesses, and infected wounds). In cats, it was 96.8% effective against skin infections.[3]
Contraindications include known allergies to cefovecin or antibiotics containing β-lactam rings such as penicillin or cephalosporins. Adverse reactions can include anaphylaxis. It is not for use in humans and should be kept out of reach of children. People with similar known allergies should avoid dermal contact when handling cefovecin.[citation needed]
In dogs, adverse effects may include lethargy, decreased appetite, vomiting, diarrhea, blood in feces, and flatulence. In cats, adverse reactions may include vomiting, diarrhea, decreased appetite, lethargy, odd hyperactive behavior, and inappropriate urination. Mildly increased serumalanine transaminase (ALT) andgamma-glutamyltransferase may also occur.[3]
Other reported events in dogs and cats include death, tremors/ataxia, seizures,anaphylaxis, acute pulmonary edema, facial edema, injection site reactions (alopecia, scabs, necrosis, and erythema), hemolytic anemia, salivation, pruritus, lethargy, vomiting, diarrhea, andinappetence.[6]
Cefovecin interferes with the synthesis of bacterial cell walls, by binding topenicillin binding proteins. Due to high protein-binding, it is not effective against species ofPseudomonas orEnterococcus. The maximum anti-bacterial activity occurs approximately two days after cefovecin has been administered.[7]
In the dog, thehalf-life of cefovecin is 5.5 days, and in the cat, it is 6.9 days.[7] In birds and reptiles, the half-life is only a few hours, much shorter than in dogs and cats.[8] In cats, 99% of cefovecin isbound toproteins in theblood plasma.[7]
Cefovecin was first authorized for use in theEuropean Union in June 2006,[9] and was approved for use in theUnited States in June 2008.[10]
